First Patient enrolled in Ph 2 Trial of Ethanol-Free Carmustine in High-Dose Chemotherapy Prior to Transplant in Patients with HL or NHL
“The initiation of this trial further demonstrates VIVUS’ commitment and ability to advance innovative drug formulations that can improve patient outcomes,” said John Amos, Chief Executive Officer at VIVUS LLC. “Conditioning regimens prior to AHCT are arduous, and VI-0609 may help to reduce patient burden by improving the safety profile and enabling shorter infusion times compared with high-dose BiCNU. Consequently, we believe that VI-0609 will provide benefit to treatment centers, health systems and patients.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.